This $705,334 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the role of the cyclin-dependent kinase 9 (CDK9) in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The key objectives are to elucidate the molecular mechanisms by which CDK9 regulates IPF development and progression, screen CDK9 inhibitors for efficacy against fibrosis, and evaluate the therapeutic potential of a top-performing CDK9 inhibitor in a mouse model of lung injury and fibrosis. The grant was awarded to The Methodist Hospital Research Institute Division, a leading academic medical research center, with the goal of generating pre-clinical data to support future development of a CDK9 inhibitor-based therapy for IPF, an unmet medical need with poor prognosis. The grant period extends from January 1, 2025 to November 30, 2028.
Generated 3/4/25, 6:33 AM